8 Best CBD Stocks to Buy Right Now
The CBD sector is showing signs of entering a more mature and sustainable growth phase. This shift is drawing renewed investor attention to CBD stocks.
Posts Tagged ‘Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’
10 Best European Growth Stocks to Buy
European growth stocks are getting another look as investors search for earnings growth outside the usual U.S. mega-cap playbook.
10 Best Fast Growth Stocks to Invest In Now
Fast-growth stocks are getting a fresh look as the market no longer only looks at a small group of mega-cap names.
Jazz Pharmaceuticals plc (JAZZ) Reports $1.2 Billion Q4 Revenue, Beats $1.17B Estimate
On February 25, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported Q4 revenue of $1.2 billion, exceeding consensus estimates of $1.17 billion and marking 10% year-over-year growth...
11 Best Pot Stocks to Buy According to Hedge Funds
The global cannabis industry is undergoing a structural transformation as legalization expands for both medical and adult use across multiple regions.
Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the mid-cap stocks to buy according to top investors.
Top Investors’ Stock Portfolio: 10 Mid-cap Stocks To Buy
The Fed's change from higher interest rates to rate cuts has caused what Amy Y.
Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial
In a statement, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said that it recorded positive results for its phase 3 clinical trial for Ziihera, in combination with chemotherapy, with...
Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the stocks with low beta that can beat market volatility.
13 Stocks With Low Beta That Can Beat Market Volatility
In August, consumer spending and income both exceeded expectations.
Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the most undervalued NASDAQ stocks to buy now.
14 Most Undervalued NASDAQ Stocks to Buy Now
On September 22, stocks surged to mark a third consecutive day of record-high closes, driven by hopes that the AI trade and additional Fed policy easing would boost the upward...
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) continues to advance its mission to transform patient lives through innovative therapies for conditions with limited treatment options.
10 Best Pharma Stocks to Buy According to Billionaires
Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United...
Jazz Pharmaceuticals plc (JAZZ) Wins FDA Nod for Modeyso in Rare Pediatric Brain Tumors
Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharmaceutical leader, develops and commercializes therapies for complex conditions in oncology, neuroscience, and sleep medicine...
12 Cheap Healthcare Stocks to Buy Now
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there...
Jazz Pharmaceuticals (JAZZ) Price Target Raised After Modeyso Commercial Strategy Update
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the best mid-cap stocks with huge upside potential.
12 Best Mid-Cap Stocks with Huge Upside Potential
The Federal Reserve's favored inflation indicator showed a modest increase in July inflation, suggesting that President Donald Trump's tariffs are having an impact on the American...
Jazz Pharmaceuticals plc (JAZZ) Wins FDA Accelerated Approval for Modeyso™ Brain Cancer Therapy
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a specialty pharmaceutical company focused on neuroscience, oncology, and rare diseases, with a global presence and products including...
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the...
10 Overlooked Healthcare Stocks to Invest in
Most Americans have endured the frustration of having their health insurance denied, often with no resolution even after contacting carriers by phone and email.
Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains ‘Buy’ Rating
On July 22, 2025, Morgan Stanley maintained its ‘Buy’ rating on JAZZ. However, the analyst lowered its price target slightly from $166 to $165.
10 Most Undervalued Foreign Stocks to Buy According to Analysts
The dominance of U.S.
Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the 7 most undervalued pot stocks to buy according to analysts.
7 Most Undervalued Pot Stocks To Buy According To Analysts
The global cannabis market was worth $26.86 billion in 2022, Spherical Insights & Consulting data shows.
Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the 30 stocks expected to beat the market by 20 percentage points this year.
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the 13 Biotech Stocks with Huge Upside Potential.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ)
On June 3, Needham analyst Ami Fadia reaffirmed a Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and raised the price target slightly from $200 to $202.
Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that the Phase 3 IMforte trial has established a new milestone in the treatment of extensive-stage small cell lung cancer...
Billionaire Ray Dalio’s Bridgewater’s 10 Stock Picks with Huge Upside Potential
Up until February 18, 2025, the stock market seemed poised to replicate the 2020-2022 bull run.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
10 Cash-Rich Mid Cap Stocks To Buy Now
Cash flow is the money moving in and out of a business over a set period.
14 Best 52-Week High Stocks To Buy According to Analysts
After two years of substantial gains to record highs, exhaustion in the US equity markets is slowly kicking in.
8 Most Undervalued Pot Stocks to Buy According to Analysts
A decade ago, the cannabis industry was in full swing as stock valuations exploded to record highs in states across the country legalizing pot use for medicinal and recreational...
10 Best Immunotherapy Stocks to Buy Now
The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.
8 Best Stocks to Buy for High Returns in 2024
The broader market reached new record highs on October 11, driven by financial stocks posting stronger-than-expected quarterly results.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
Piper Sandler’s Top Technical Stock Picks: 20 Best Stocks
The start of October has seen another wild swing for markets.
8 Most Undervalued Growth Stocks To Buy According To Wall Street Analysts
Analysts and the market blamed the Fed for not cutting the interest rate earlier in July.
10 Stocks with Biggest Upside Potential According to Hedge Funds
The US equities saw a strong move after the September jobs report exceeded the economists’ estimates.
Seth Klarman Stock Portfolio: Top 10 Stock Picks
Seth Klarman, the founder and CEO of Baupost Group, is a prominent figure in the investment industry, with his hedge fund ranking as the 12th largest globally.
8 Best Cheap Growth Stocks To Invest In Now
The current market data shows that the economy of the United States is normalizing, especially with an active Federal Reserve, global stimulus from China, and higher consumption...
12 Best Biotech Stocks To Invest In According To Hedge Funds
As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1," the size of the global biotechnology industry was assessed to be worth $1.38 trillion in 2023 and...
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Top 10 ADR Stocks To Buy According to Hedge Funds
Diversifying an investment portfolio is one of the best ways of spreading risk and minimizing the impact of heightened volatility.
8 Best Pot Stocks to Buy
The history of the cannabis industry is riddled with changes and conflicting legislation.
5 High Growth Value Stocks to Invest in According to Seth Klarman
In this piece, we will take a look at the five high growth value stocks to invest in according to Seth Klarman.
Hedge Fund Resource Center
